mProX™ Human SLC34A2 Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;U251;U87

Target Classification

Kinase Cell Lines

Target Research Area

Orphan Receptor Research

Related Diseases

Pulmonary Alveolar Microlithiasis; Testicular Microlithiasis

Gene ID

Human:10568

UniProt ID

Human:O95436

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SLC34A2 is a gene that plays a role in various medical conditions. In the context of non-small cell lung cancer (NSCLC), SLC34A2 gene fusions can be detected using RNA-based next-generation sequencing (NGS) assays. This study found that RNA-based NGS had a high concordance rate with fluorescence in situ hybridization (FISH) testing for detecting ALK, RET, and ROS1 fusions in NSCLC cytology specimens. However, RNA-based NGS had a high failure rate, so additional testing methods may be necessary for comprehensive genomic profiling. In the case of pulmonary alveolar microlithiasis (PAM), a rare lung disease, SLC34A2 gene mutations are implicated. PAM is characterized by the presence of calcified microliths in the lungs and can be diagnosed through radiological examination, SLC34A2 mutation analysis, or the presence of microliths in bronchoalveolar lavage or sputum. Lung transplantation is currently the only effective treatment for PAM. Additionally, SLC34A2 is involved in intestinal phosphate absorption, particularly in young mice, where increased expression of SLC34A2 and paracellular phosphate permeability contribute to higher intestinal phosphate absorption.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SLC34A2 Stable Cell Line (S01YF-1023-PY151). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Williams (Verified Customer)

What is the role of SLC34A2 in embryonic stem cells? Sep 16 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

SLC34A2 is involved in the early gene activation (EGA)-like expression program in human embryonic stem cells, as indicated by studies showing that transient DUX4 expression activates this program. Sep 16 2020

chat Alex Jones (Verified Customer)

How does SLC34A2 affect pulmonary alveolar microlithiasis? Dec 04 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Variants in SLC34A2 can impair phosphate transport, contributing to the pathology of pulmonary alveolar microlithiasis. Dec 04 2020

Published Data

Fig.1 Knock down of SLC34A2 in glioma cells.

U251 and U87 cell lines were subjected to infection with either sh-SLC34A2 or sh-scramble constructs, followed by an assessment of the knockdown effectiveness through both qRT-PCR and Western blot analysis techniques.

Ref: Bao, Zhijun, Lihua Chen, and Shiwen Guo. "Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma." Journal of Cellular Biochemistry 120.6 (2019): 10205-10214.

Pubmed: 30592329

DOI: 10.1002/jcb.28305

Research Highlights

Diks, John. et al. "Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in¬†situ hybridization." Cancer cytopathology, 2023.
The utility of an RNA-based NGS assay for detecting genomic alterations in non-small cell lung cancer (NSCLC) cytology specimens was evaluated in this study. The need for genomic profiling to identify actionable alterations in NSCLC was also addressed. Panel-based testing, specifically next-generation sequencing (NGS), was shown to be a preferred method for simultaneously interrogating multiple alterations. Results obtained from this assay were compared to fluorescence in situ hybridization (FISH) testing. The study supports the use of RNA-based NGS as a reliable method for detecting genomic alterations in NSCLC.
Diks, John. et al. "Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in¬†situ hybridization." Cancer cytopathology, 2023.
Pubmed: 37747438 DOI: 10.1002/cncy.22766

Batesh, Duaa. et al. "Pulmonary alveolar microlithiasis: a rare case report from Syria." Annals of medicine and surgery (2012), 2023.
The following report details a case of pulmonary alveolar microlithiasis (PAM), a scarce condition characterized by symptoms such as chronic coughing, difficulty breathing, and chest discomfort. The majority of recorded cases originate from Turkey, with a prevalence rate of 1.85 in 1 million. However, there is a lack of documented cases from Syria in the medical literature. Hence, this article presents the initial documented case from Syria, providing a comprehensive analysis of the patient's condition and treatment.
Batesh, Duaa. et al. "Pulmonary alveolar microlithiasis: a rare case report from Syria." Annals of medicine and surgery (2012), 2023.
Pubmed: 37663718 DOI: 10.1097/MS9.0000000000001060